Curcumin Lowers Serum Lipids And Uric Acid In Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial
Notes for this study:
||(mg/dl). Placebo: before 5.39±0.69, after 5.64±0.72. Curcumin: before 5.23±1.02, after 4.80±0.85
|Number of Subjects
||18-29, 30-44, 45-64, 65+
In a randomized trial with unclear blinding or use of placebos, 102 participants with nonalcoholic fatty liver disease were assigned to take 1,000 mg of a phystosomal curcumin extract or control daily for 8 weeks.
The primary outcome was liver fat as assessed by Color Doppler Ultrasonography, however, this wasn't reported on. There was a statistically significant reduction in total cholesterol, non-HDL cholesterol, LDL-C, triglycerides and uric acid in the curcumin group compared with placebo. There was no statistically significant change in HDL-C, fasting glucose, insulin, insulin resistance, or beta cell function between groups.